|Bid||0.006 x 431587700|
|Ask||0.007 x 267473600|
|Day's Range||0.006 - 0.007|
|52 Week Range||0.006 - 0.021|
|PE Ratio (TTM)||-1.75|
|Earnings Date||Mar 1, 2016 - Mar 5, 2016|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||0.25|
MELBOURNE, Australia, Sept. 21, 2017-- Genetic Technologies Limited, a molecular diagnostics company specialising in cancer genomics, and provider of BREVAGen plus ®, a first-in-class, clinically validated ...
Research Desk Line-up: Enzymotec Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Genetic ...
Genetic Technologies Limited , a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for non-hereditary ...